The Longer, the Better: Continuous Glucose Monitoring Use for ≥90% Is Superior to 70%-89% in Achieving Tighter Glycemic Outcomes in Children with Type 1 Diabetes
Language English Country United States Media print-electronic
Document type Journal Article
PubMed
39761072
DOI
10.1089/dia.2024.0472
Knihovny.cz E-resources
- Keywords
- CGM, glucose monitoring, pediatrics, registry, type 1 diabetes,
- MeSH
- Time Factors MeSH
- Diabetes Mellitus, Type 1 * blood drug therapy MeSH
- Child MeSH
- Glycated Hemoglobin analysis MeSH
- Hypoglycemic Agents therapeutic use MeSH
- Continuous Glucose Monitoring MeSH
- Blood Glucose * analysis MeSH
- Humans MeSH
- Adolescent MeSH
- Child, Preschool MeSH
- Registries MeSH
- Glycemic Control * methods MeSH
- Blood Glucose Self-Monitoring * methods MeSH
- Check Tag
- Child MeSH
- Humans MeSH
- Adolescent MeSH
- Male MeSH
- Child, Preschool MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Geographicals
- Czech Republic MeSH
- Names of Substances
- Glycated Hemoglobin MeSH
- hemoglobin A1c protein, human MeSH Browser
- Hypoglycemic Agents MeSH
- Blood Glucose * MeSH
Objective: The recommended threshold for the time spent on continuous glucose monitoring (CGM) is established at 70%. However, glucose outcomes in children with type 1 diabetes (CwD) using CGM for a different proportion of time within this threshold have not been evaluated yet. The study aims to compare glycemic parameters among CwD who spent 70%-89% and ≥90% on CGM using the population-wide data from the Czech national pediatric diabetes registry ČENDA. Methods: CwD aged <19 years who used real-time CGM >70% of the time and did not change the type of therapy throughout the year 2023 were included and divided into two groups based on the time they spent on CGM-70%-89% versus ≥90%. HbA1c, times in standard glycemic ranges, mean glucose, and coefficient of variability (CV) were compared between the groups and by treatment modalities. Results: Data from 1977 CwD (1035 males and 942 females) were evaluated. Among them, 404 participants (20.4%) used CGM 70%-89% of the time, and 1573 participants (79.6%) ≥90% of the time. Compared with the 70-89% group, the ≥90% CGM users achieved significantly lower HbA1c levels (51 mmol/mol, 6.8% vs. 58 mmol/mol, 7.4%, P < 0.001), higher time in range (72% vs. 60%, P < 0.001), and lower mean glucose and CV (8.1 mmol/L, 146 mg/dL vs. 9.1 mmol/L, 164 mg/dL and 37% vs. 40%, respectively, both P < 0.001). Analogous results were seen irrespective of the treatment modality. The differences persisted after propensity score adjustment. Conclusion: CGM use for ≥90% is associated with tighter glycemic control compared with 70%-89% use. Therefore, it is essential to motivate CwD to use CGM for the longest possible time and search for suitable options to overcome barriers in uninterrupted CGM monitoring.
1st Faculty of Medicine Charles University Prague Czechia
Department of Pediatrics Hospital Ceske Budejovice Budejovice Czechia
Department of Pediatrics Masaryk Hospital Usti nad Labem Czechia
Department of Pediatrics Motol University Hospital and 2 Faculty of Medicine Prague Czechia
Department of Pediatrics Motol University Hospital and 2nd Faculty of Medicine Prague Czechia
Department of Pediatrics University Hospital Brno Brno Czechia
Department of Pediatrics University Hospital Hradec Kralove Kralove Czechia
Department of Pediatrics University Hospital Olomouc Olomouc Czechia
Department of Pediatrics University Hospital Ostrava Ostrava Czechia
Department of Pediatrics University Hospital Plzen Plzen Czechia
References provided by Crossref.org
Global Inequities in Diabetes Technology and Insulin Access and Glycemic Outcomes